Nationwide genetic analysis for molecularly unresolved cystic fibrosis patients in a multiethnic society: implications for preconception carrier screening

Abstract

BackgroundPreconception carrier screening for cystic fibrosis (CF) is usually performed using ethnically targeted panels of selected mutations. This has been recently challenged by the use of expanded, ethnically indifferent, pan‐population panels. Israel is characterized by genetically heterogeneous populations carrying a wide range of CFTR mutations. To assess the potential of expanding the current Israeli preconception screening program, we sought the subset of molecularly unresolved CF patients listed in the Israeli CF data registry comprising ~650 patients.MethodsAn Israeli nationwide genotyping of 152 CF cases, representing 176 patients lacking molecular diagnosis, was conducted. Molecular analysis included Sanger sequencing for all exons and splice sites, multiplex ligation probe amplification (MLPA), and next‐generation sequencing of the poly‐T/TG tracts.ResultsWe identified 54 different mutations, of which only 16 overlapped the 22 mutations included in the Israeli preconception screening program. A total of 29/54 (53.7%) mutations were already listed as CF causing by the CFTR2 database, and only 4/54 (7.4%) were novel. Molecular diagnosis was reached in 78/152 (51.3%) cases. Prenatal diagnosis of 24/78 (30.8%) cases could have been achieved by including all CFTR2‐causing mutations in the Israeli panel.ConclusionsOur data reveal an overwhelming hidden abundance of CFTR gene mutations suggesting that expanded preconception carrier screening might achieve higher preconception detection rates.

Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul

“…No mutations were found in 12 (4.8%) patients. Studies from Iran and Israel utilizing the same methods revealed similar mutation detection rates of 81.9% and 89.3%, respectively . A study conducted in Syria revealed that 78% of the total mutations were detectable.…”

Next-Generation Sequencing for Molecular Diagnosis of Cystic Fibrosis in a Brazilian Cohort

“…Predictive analysis of the possible effect of this insertion in the MutationTaster program was positive for pathogenicity. As a class I mutation, it leads to complete or near-complete loss of CFTR activity [12,40]. Even with complete sequencing of CFTR, 12 patients were identified with only one CFTR variant.…”

The Q359K/T360K mutation causes cystic fibrosis in Georgian Jews

“…All patients underwent molecular analysis for the 15 most common mutations in Israel including Q359K/T360K, and CFTR Sanger sequencing when the mutation panel was negative [7]. Patients with ≥1 Q359K/T360K mutation meeting diagnostic criteria for CF [8] were included.…”